Medtronic plc (MDT) · Sep 1, 2026 · Earnings

Medtronic beats Q1 estimates and lifts FY27 guide, but extra week flatters growth

Beat — non-GAAP EPS $1.45 vs ~$1.39 consensus

Medtronic delivered a clean Q1 beat and raised FY27 targets, though a 53rd fiscal week supplied a large lift to headline growth.

The quarter cleared the market's bar. Published expectations were roughly $1.39 for adjusted EPS and $9.64 billion of revenue; Medtronic delivered $1.45 and $9.756 billion, respectively.

MetricQ1 FY27Q1 FY26Published expectation
Revenue$9.756B (Financial Highlights)$8.578B (Income Statement)~$9.64B
Non-GAAP diluted EPS$1.45 (GAAP to Non-GAAP Reconciliation)$1.26 (GAAP to Non-GAAP Reconciliation)~$1.39
Non-GAAP operating margin23.7% (GAAP to Non-GAAP Reconciliation)23.6% (GAAP to Non-GAAP Reconciliation)—
Free cash flow$1.290B (Cash Flow statement)$584M (Cash Flow statement)—
FY27 organic revenue growth guide7.25%-7.75% (Guidance)Prior: 6.75%-7.25%—
FY27 non-GAAP EPS guide$5.94-$6.00 (Guidance)Prior: $5.90-$6.00—

The beat was broad, but not entirely clean. Organic revenue rose 13.7%, with Cardiovascular up 18.9%, Neuroscience up 9.3%, and Medical Surgical up 10.2% (Worldwide Revenue). The company also said, "The company today raised its FY27 organic revenue growth and EPS guidance." 〔0〕

The calendar supplied a meaningful part of the headline acceleration. FY27 includes 53 weeks, and Medtronic estimates the extra week added approximately $570 million to Q1 organic growth (Worldwide Revenue). That is roughly half of the year-over-year revenue increase, so the underlying operating gain is closer to the high-single-digit range than the reported 13.7% organic figure.

The forward revision is positive but modest. Revenue-growth guidance moved up by 50 basis points at both ends, while the EPS range increased only at the low end and its midpoint moved from $5.95 to $5.97. The limited EPS revision, alongside just 10 basis points of non-GAAP operating-margin expansion, suggests the upside was more about execution and volume than a major profitability reset.

Net: a real beat, with a small upgrade rather than a wholesale change in the story. Strong Cardiovascular growth, higher cash generation, and raised guidance outweigh the calendar distortion; however, the extra week and restrained EPS upgrade keep this from reading as a large expectation reset.

What to watch next

Q2 earnings report

Original filing on SEC EDGAR

More Medtronic plc news

Medtronic beats Q1 estimates and lifts FY27 guide, but extra week flatters growth | MDT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.